Stockscreener 앱 받기
2.97
1.37%
0.04
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
tScan Therapeutics sees $385,768 purchase by Lynx1 Capital - Investing.com
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges - Investing.com India
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges By Investing.com - Investing.com South Africa
Wedbush Cuts Earnings Estimates for TScan Therapeutics - Defense World
Equities Analysts Offer Predictions for TCRX FY2026 Earnings - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLC - Defense World
HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics (NASDAQ: TCRX) Issues Report on Updated Phase 1 Trial Data for ALLOHA Program**On December 9, 2024, TScan Therapeutics, Inc. released a comprehensive report on the latest developments surrounding its ALLOHA ™ Phase 1 trial - Defense World
The Analyst Landscape: 5 Takes On TScan Therapeutics - Benzinga
HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from Needham & Company LLC - MarketBeat
TScan Therapeutics Announces Promising Phase 1 Trial Results - TipRanks
TScan Therapeutics to Present Updated Data from the Ongoing - GlobeNewswire
Tscan Therapeutics to Present Updated Data from the Ongoing Alloha?? Phase 1 Heme Trial During Oral Session At the 66Th American Society of Hematology Annual Meeting and Exposition - Marketscreener.com
TScan's Blood Cancer Treatment Shows Breakthrough 92% Relapse Prevention in Phase 1 Trial Data - StockTitan
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - GlobeNewswire
TScan Therapeutics Named Top Workplace in Massachusetts for Third Straight Year - StockTitan
TScan Therapeutics to Host Virtual KOL Event to Discuss - GlobeNewswire
TScan Therapeutics to Host KOL Event on Phase 1 Blood Cancer Trial Data at ASH - StockTitan
TScan issues stock in loan conversion - Investing.com
LMR Partners LLP Reduces Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World
FY2024 EPS Estimate for TScan Therapeutics Lifted by Analyst - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat
TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy
Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
TScan Reports Zero Relapses in Key Trial Despite 74% Revenue Drop; $271M Cash Runway - StockTitan
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register
TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St
TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan
2.88%
2.65%
자본화:
|
볼륨(24시간):